Aviragen Therapeutics (AVIR) Announces Publication of Preclinical Data Highlighting Potent Activity of AT-527 Against SARS-CoV-2

Go back to Aviragen Therapeutics (AVIR) Announces Publication of Preclinical Data Highlighting Potent Activity of AT-527 Against SARS-CoV-2

Atea Pharmaceuticals Announces Publication of Preclinical Data Highlighting Potent Activity of AT-527 Against SARS-CoV-2

February 8, 2021 4:01 PM EST

BOSTON, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea), a clinical-stage biopharmaceutical company, today announced the publication of new data highlighting the highly potent in vitro antiviral activity of AT-527 against SARS-CoV-2. AT-527 is an orally administered, direct-acting antiviral developmental agent derived from Ateas purine nucleotide prodrug platform. The new findings are available in a manuscript published online in... More